Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039264 | 0.86 | GRM2 (0.40) | GRM2F10KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3035177 | 0.86 | GRM2 (0.40) | GRM2F10KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3043125 | 0.86 | GRM2 (0.44) | GRM2F10 | |
| SCHEMBL3044403 | 0.85 | MAOA (0.54) | GRM2F10 | |
| SCHEMBL3043259 | 0.83 | MAOA (0.40) | GRM2F10KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3045229 | 0.79 | MAOA (0.51) | F10 | |
| SCHEMBL5762074 | 0.79 | F10 (0.45) | GRM2F10 | |
| SCHEMBL6040255 | 0.79 | F10 (0.45) | GRM2F10 | |
| SCHEMBL3036167 | 0.78 | MAOB (0.60) | F10 | |
| SCHEMBL3043201 | 0.77 | MAOA (0.53) | GRM2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | GRM2 2255/4885F10 4479/4885KDM4E 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.